Skip to content

Samsung Biologics Faces Mounting Losses in Day 5 Strike

South Korea's Samsung Biologics is grappling with its first strike in over a decade, now on day five as of Tuesday. Unionized staff are holding firm on calls for steep wage hikes and bonuses,...

By News Analysis India · · Updated · 1 min read

South Korea's Samsung Biologics is grappling with its first strike in over a decade, now on day five as of Tuesday. Unionized staff are holding firm on calls for steep wage hikes and bonuses, disrupting operations at this key player in global biologics production. The walkout began Friday, drawing 2,800 participants from a 4,000-strong union—a milestone event for the 2011-founded firm. Frustrations center on inadequate pay amid rising living costs and company profits. Workers seek 14% increases in core and performance pay, 30 million won ($20,390) one-off payments each, and 20% of annual profits as bonuses. Management's 6.2% proposal has been rejected outright. Fresh talks on Monday failed to yield agreement, with two more rounds eyed by week's end. The union eyes a 'work-to-rule' strategy post-strike from Wednesday, enforcing strict adherence to rules to hamper efficiency. Economic fallout is severe: a prior partial strike last month drained 150 billion won ($101.5 million), and this one could cost 640 billion won—about half of Q1 sales. Such figures underscore the high stakes for both labor and capital. Responding to ministry mediation, company reps stress dialogue's primacy, imploring the union to curb 'unreasonable' claims. A prior mediation faltered over the union's push to swap its full negotiation lineup. This clash arrives as Samsung Biologics scales up for international pharma giants. Prolonged unrest risks contracts and reputation, prompting questions on sustainable labor practices in high-tech manufacturing. Resolution hangs in the balance of upcoming sessions.